9 results found
Searchresult 1 - 9 of 9. You filter by “Competition” and “Health care consumers”.
ACM extends its investigation into the orphan drug CDCA manufactured by Leadiant. The investigation focuses on the pricing of the drug, and on possible abuse of a dominant position.
Further investigation needed into merger of three geriatric-care providers in the south of the Netherlands
Dutch health care providers Stichting Schakelring, Stichting De Riethorst Stromenland and Stichting Volckaert wish to merge. Further investigation is needed into the merger’s effects in the markets for geriatric-rehabilitation care and post-acute rehabilitation services.
ACM conducted a sector inquiry into TNF alpha inhibitors. The expiration of patents has led to lower prices. To guarantee their affordability in the future, competitors must be able to gain a solid position on the Dutch market.
ACM Working Paper: Reconciling competition and IP law: the case of patented pharmaceuticals and dominance abuse
Even if medicines have a patent, competition law can deal with excessive prices or abuse of a dominant position.
Consumers look for certainty when choosing a health insurance. This has been revealed by the Health Care Monitor.